“We Can Work It out”: The Development of a Consensus Approach to Decision Making in Allogeneic Stem Cell Transplantation in the UK  by Wynn, Robert F. et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S238323
“We Can Work It out”: The Development of a Consensus
Approach to Decision Making in Allogeneic Stem Cell
Transplantation in the UK
Robert F. Wynn 1, Paul Veys 2, Colin G. Steward 3, Ajay Vora 4,
Roderick Skinner 5, Brenda Gibson 6, Mark Velangi 7,
Rachael Hough 8, Michael Potter 9, Josu de la Fuente 10,
Persis Amrolia 11, Owen Smith 12. 1 Royal Manchester Children’s
Hospital, Manchester, United Kingdom; 2 Great Ormond Street
Hospital for Children, London, United Kingdom; 3 BMT, Royal
Hospital for Sick Children, Bristol, United Kingdom; 4 BMT/Paed
Haematology, Shefﬁeld Children’s Hospital, Shefﬁeld, United
Kingdom; 5 Paediatric and Adolescent Haematology / Oncology /
BMT, Newcastle University, Royal Victoria Inﬁrmary, Newcastle ,
United Kingdom; 6 Schiehallion Day Care Unit, Royal Hospital
for Sick Children, Glasgow, Scotland, United Kingdom;
7 Birmingham Children’s Hospital, Birmingham, United
Kingdom; 8University College Hospital London, London, United
Kingdom; 9Department of Haematology, Royal Marsden
Hospital, Sutton, United Kingdom; 10Department of Paediatrics,
Imperial College London, London, United Kingdom; 11 Blood and
Marrow Transplantation Program, Great Ormond Street
Hospital for Children NHS Trust, London, United Kingdom;
12Our Lady’s Children’s Hospital Crumlin, Dublin, Ireland and
Beki James, Leeds General Inﬁrmary, Leeds, United Kingdom
Introduction: Blood and marrow transplantation is a low
volume, high risk specialty. Institutional practices vary
considerably. Consensus practice is important for physician
and family conﬁdence and to optimize patient outcomes
during stem cell transplantation with best practice and as a
platform for research. The 12 pediatric/adolescent trans-
plant centers of the UK and Ireland are increasingly
collaborative and this report summarizes the efforts of that
groups and commends them to other national pediatric
BMT groups.
Materials (or patients) and methods: The Group’s activ-
ities over the last 7 years are reviewed in the following
areas: a) National Audit Meeting in which all transplants
performed from the previous year are in a single national
meeting attended by physicians, nurses and data managers
from each center. Instructive cases and all transplant
related deaths are speciﬁcally highlighted. There have been
now 9 such annual meetings. An external auditor attends.
b) Twice yearly meetings attended by transplant centers in
which protocols are drawn up and consensus indications
discussed. c) Since 2012 there has been a national, monthly
video conference attended by transplant teams. Difﬁcult
cases referred for transplant and difﬁcult cases during
transplant are discussed. An agenda is circulated in
advance of the meeting and there is a summary of the
discussion (as meeting minutes) circulated afterwards. A
separate video MDT has been held with metabolic disease
pediatricians for particular metabolic related SCT cases. d)
The group has agreed consensus guidelines for transplant
for group members.
Results: All transplants performed in the UK have
been discussed at national audit meetings. There is a
median of 300 transplants per annum. There is a national,
annually updated, indication list for stem cell transplantation
in children for National Health Service purchasers.
National protocols for stem cell transplant in AML, ALL,
hemoglobinopathy, metabolic diseases and constitutionaland acquired aplastic anaemia. National video MDT are held
monthly and pre-HCT (75%) and post-HCT patients are
discussed. Parallel to these increasing face-to-face contacts
there is increasing email contact between the group between
meetings.
Discussion: We have found these national, increasingly
frequent joint meetings to be extremely useful and we
commend them to other national groups. We also believe
that the opportunity to discuss individual cases with
such a national group is not only helpful to patient
management but is easily seen - for families and pro-
fessionals - to be important to patient management and
generates conﬁdence in the complicated transplant
process.324
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Allogeneic HSCT remains the only curative option for pa-
tients with B-Thalassemia major. Outcome of Thalassemia
patients depends on class of Thalassemia, type of donor and
type of preparative conditioning regimen. Our objective
herein was to review the outcome of all children who
received HSCT for different types of hemoglobinopathy be-
tween the years 1998-2014 in Rambam Medical Center,
Israel.
Patients and Methods: 45 HSCT were done to 37 children,
33 Thalassemia and 4 Sickle Cell Anemia patients. Median
age at HSCT was 7.8 years (range 0.5-22 yr). Of total 33
Thalassemia patients, 25 had 1 HSCT and 8 children needed
second HSCT. 15 patients had class 1 or 2 and 18 had class 3
of Thalassemia. 38 patients received stem cells from
matched related donors, 4 from matched unrelated donors
and 3 from unrelated cord blood. Conditioning regimen
included Protocol P26 in 24 patients, 2 of them received
modiﬁed Protocol P26 with Treosulphan instead of
Busulphan; 10 patients were conditioned with protocol
Busulphan, Cyclophosphamide, with or without Anti-
tymoglobulin; 7 children had partially T-cell depleted pro-
tocol with Busulphan, Cyclophosphamide, Fludarabine and
ATG without immunosuppression after infusion of graft and
3 patients received protocol with Treosulphan, Fludarabine,
Thiotepa.
Results: Overall survival for the whole group was 88% and
event free survival 80%. 9 patients rejected the graft: 5 had
primary rejection and 4 had secondary engraftment failure
with median time of rejection 8.7 months (range 1-17
months). 2 of 9 rejected patients successfully engrafted
after second HSCT and 2-rejected second HSCT as well. 75%
of all successfully engrafted patients have full donor
chimerism, 25% mixed stable chimerism. Incidence of
acute graft versus host disease (GVHD) was 24%, grade 3-4
